COVID-19 vaccines coverage and effectiveness against SARS-CoV-2 infection among residents in the largest Health Authority of Lazio region (Italy): a population-based cohort study

被引:6
作者
Fano, Valeria [1 ]
Coviello, Enzo [2 ]
Consonni, Dario [3 ]
Agresta, Alessandro [4 ]
Orsini, Nicola [5 ]
Crielesi, Alessia [1 ]
Miglietta, Antonio Salvatore [1 ]
Pasqua, Caterina [1 ]
Vairo, Francesco [4 ]
Vivaldi, Fabio [1 ]
De Angelis, Giuseppe [1 ]
Colaiocco, Giovanni [1 ]
Fabiani, Massimo [6 ]
机构
[1] Local Hlth Author Asl Roma 2, Dept Publ Hlth, Viale Battista Bardanzellu 8, I-00155 Rome, Italy
[2] Med Doctor, Bari, Italy
[3] Fdn IRCCS Ca Granda Osped Maggiore Policli, Epidemiol Unit, Milan, Italy
[4] Surveillance & Control Infect Dis, Reg Serv Epidemiol, Lazio Region, Italy
[5] Karolinska Inst, Dept Global Publ Hlth, Stockholm, Sweden
[6] Ist Super Sanita, Dept Infect Dis, Rome, Italy
关键词
Booster dose; cohort study; SARS-CoV-2; infection; Socio-demographic characteristics; vaccine effectiveness; waning effect; vaccine coverage; COVID-19; VACCINATION CAMPAIGN; HOSPITAL ADMISSIONS; MORTALITY; SCOTLAND; DEATHS; TIME; AREA;
D O I
10.1080/14760584.2022.2080057
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background The waning of the protective effect of COVID-19 vaccines and timing of booster doses are debated. Methods Population-based cohort study in the largest Health-Authority of Lazio region, Italy, on 946,156 residents aged 12+ (study period: 1 January 2021-10 January 2022). Vaccine effectiveness (VE) against any SARS-CoV-2 infection (symptomatic or asymptomatic) was estimated through multivariable negative-binomial models using unvaccinated person-time as a reference. Results The primary vaccination cycle was completed by 81% of residents; of these, 45% received a booster dose. Vaccine coverages were lower for foreigners, and people living in deprived areas, families with children aged 0-11, and households size 1 or 6+. Overall, VE waned from 71% (95% Confidence Interval (CI) 70-73%) 1 month after the second dose to 43% (CI 41-45%) after 4 months and 24% (CI 21-27%) after 6 months, especially in the elderly aged 70+. We observed a prompt restore of VE 15-19 days after the booster dose (69%, CI 67-70%). Conclusions Our results support the recommendation of a booster dose 4 months after completion of the primary cycle, giving priority to elderly and fragile individuals. The lower vaccine coverage among social disadvantaged subgroups suggests the need of targeted communication and interventions.
引用
收藏
页码:1147 / 1157
页数:11
相关论文
共 35 条
  • [1] [Anonymous], 2021, ADDENDUM EVALUATION
  • [2] Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
    Bar-On, Yinon M.
    Goldberg, Yair
    Mandel, Micha
    Bodenheimer, Omri
    Freedman, Laurence
    Kalkstein, Nir
    Mizrahi, Barak
    Alroy-Preis, Sharon
    Ash, Nachman
    Milo, Ron
    Huppert, Amit
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15) : 1393 - 1400
  • [3] Barda N., 2021, CLIN MICROBIOL INFEC, V28, pSS1198
  • [4] Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
    Barda, Noam
    Dagan, Noa
    Cohen, Cyrille
    Hernan, Miguel A.
    Lipsitch, Marc
    Kohane, Isaac S.
    Reis, Ben Y.
    Balicer, Ran D.
    [J]. LANCET, 2021, 398 (10316) : 2093 - 2100
  • [5] Cesaroni Giulia, 2006, Epidemiol Prev, V30, P352
  • [6] European Centre for Disease Prevention and Control, EUROPAEUENCOVID 19 C
  • [7] Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study
    Fabiani, Massimo
    Puopolo, Maria
    Morciano, Cristina
    Spuri, Matteo
    Alegiani, Stefania Spila
    Filia, Antonietta
    D'Ancona, Fortunato
    Del Manso, Martina
    Riccardo, Flavia
    Tallon, Marco
    Proietti, Valeria
    Sacco, Chiara
    Massari, Marco
    Da Cas, Roberto
    Mateo-Urdiales, Alberto
    Siddu, Andrea
    Battilomo, Serena
    Bella, Antonino
    Palamara, Anna Teresa
    Popoli, Patrizia
    Brusaferro, Silvio
    Rezza, Giovanni
    Ippolito, Francesca Menniti
    Pezzotti, Patrizio
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2022, 376
  • [8] Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021
    Fabiani, Massimo
    Ramigni, Mauro
    Gobbetto, Valentina
    Mateo-Urdiales, Alberto
    Pezzotti, Patrizio
    Piovesan, Cinzia
    [J]. EUROSURVEILLANCE, 2021, 26 (17) : 1 - 7
  • [9] Epidemiological characteristics of COVID-19 cases in non-Italian nationals notified to the Italian surveillance system
    Fabiani, Massimo
    Mateo-Urdiales, Alberto
    Andrianou, Xanthi
    Bella, Antonino
    Del Manso, Martina
    Bellino, Stefania
    Rota, Maria C.
    Boros, Stefano
    Vescio, Maria F.
    D'Ancona, Fortunato P.
    Siddu, Andrea
    Punzo, Ornella
    Filia, Antonietta
    Brusaferro, Silvio
    Rezza, Giovanni
    Dente, Maria G.
    Declich, Silvia
    Pezzotti, Patrizio
    Riccardo, Flavia
    [J]. EUROPEAN JOURNAL OF PUBLIC HEALTH, 2021, 31 (01) : 37 - 44
  • [10] Comparison of early childhood vaccination coverage and timeliness between children born to Italian women and those born to foreign women residing in Italy: A multi-centre retrospective cohort study
    Fabiani, Massimo
    Fano, Valeria
    Spadea, Teresa
    Piovesan, Cinzia
    Bianconi, Egisto
    Rusciani, Raffaella
    Salamina, Giuseppe
    Greco, Gregorio
    Ramigni, Mauro
    Declich, Silvia
    Petrelli, Alessio
    Pezzotti, Patrizio
    [J]. VACCINE, 2019, 37 (16) : 2179 - 2187